Passage Bio
Passage Bio is headquartered in United States and has $225.5M in recorded funding across 2 rounds.
- Website
- passagebio.com
- Total Funding
- $225.5M
- Last Round
- $110.0M Series BSep 2019
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds for this company. The full record is or through the API.
About
Passage Bio is a clinical-stage genetic medicines company developing therapies for rare central nervous system disorders. Its programs use gene-therapy approaches intended to address diseases associated with mutated or nonfunctional genes. The company focuses on advancing treatments for neurodegenerative conditions and improving outcomes for patients and families affected by severe neurologic disease.
Summary
Passage Bio is a Biotech company based in United States. It has raised $225.5M in total across 2 rounds, most recently a $110.0M Series B round in Sep 2019.
Funding History
Sep 2019
Sign up to see all 2 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/passage-bio"><img src="https://indexed.vc/api/badge/company/passage-bio" alt="Passage Bio on Indexed.vc" width="260" height="76" /></a>